Abstract
Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 has become an important public health issue in the world. More than 118 000 cases were confirmed around the world. The main clinical manifestations were respiratory symptoms and occasional gastrointestinal symptoms. However, there is no unified standard for the diagnosis and treatment of COVID-19. In the retrospective analysis, we report nine cases of COVID-19, describe the history of contact, clinical manifestations, the course of diagnosis and clinical treatment before, during and after treatment.
Keywords:
COVID-19; SARS-CoV-2; respiratory symptoms.
© 2020 Wiley Periodicals, Inc.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Betacoronavirus / drug effects
-
Betacoronavirus / genetics*
-
Betacoronavirus / isolation & purification
-
Betacoronavirus / pathogenicity
-
COVID-19
-
COVID-19 Testing
-
China
-
Clinical Laboratory Techniques / methods
-
Contact Tracing
-
Coronavirus Infections / diagnosis*
-
Coronavirus Infections / drug therapy*
-
Coronavirus Infections / immunology
-
Coronavirus Infections / pathology
-
Female
-
Humans
-
Interferon alpha-2 / therapeutic use*
-
Lopinavir / therapeutic use
-
Male
-
Methylprednisolone / therapeutic use
-
Middle Aged
-
Moxifloxacin / therapeutic use
-
Oropharynx / virology
-
Oxygen / therapeutic use
-
Pandemics
-
Pneumonia, Viral / diagnosis*
-
Pneumonia, Viral / drug therapy*
-
Pneumonia, Viral / immunology
-
Pneumonia, Viral / pathology
-
RNA, Viral / genetics*
-
RNA, Viral / isolation & purification
-
Retrospective Studies
-
Ritonavir / therapeutic use
-
SARS-CoV-2
-
Severity of Illness Index
-
T-Lymphocytes / drug effects
-
T-Lymphocytes / immunology
-
T-Lymphocytes / virology
-
Tomography, X-Ray Computed
Substances
-
Interferon alpha-2
-
RNA, Viral
-
Lopinavir
-
Ritonavir
-
Oxygen
-
Moxifloxacin
-
Methylprednisolone